News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Progen Industries Limited Half Yearly Financial Results
March 15, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Cancer drug development company Progen Industries (ASX: PGL, NASDAQ: PGLAF), today announced the release of its interim results for the half year ending 31 December 2005.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Australia
MORE ON THIS TOPIC
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
Infectious disease
Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership
July 10, 2025
·
2 min read
·
Tristan Manalac
Series B
Nuclidium Nets $99M Series B for Copper-Based Radiopharma Platform
July 10, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
July 9, 2025
·
1 min read
·
Dan Samorodnitsky
